A dose of 850 mg twice daily of metformin was used in this trial based on the findings of the Diabetes Prevention Program study where the same dose was reported to significantly decrease CRP levels in individuals with impaired glucose tolerance with median percent reduction of 7 and 14% in males and females respectively (Haffner et al., 2005). This evidence concerns the gene CRP and diabetes mellitus.